Canadian cannabis and pharmaceutical companies are keeping close tabs on Kiwi medicinal cannabis start-ups.
Helius Therapeutics executive director Paul Manning confirms the company has received interest from major North American cannabis companies looking to invest in New Zealand, particularly
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
